- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
36
36 companies
Travere Therapeutics
Market Cap: US$3.7b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$42.12
7D
3.2%
1Y
102.9%
Madrigal Pharmaceuticals
Market Cap: US$11.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$517.39
7D
-0.3%
1Y
57.9%
Zevra Therapeutics
Market Cap: US$571.6m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.17
7D
0.6%
1Y
33.1%
Syndax Pharmaceuticals
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$21.43
7D
2.0%
1Y
55.1%
Insmed
Market Cap: US$29.1b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$136.33
7D
-5.2%
1Y
87.7%
AnaptysBio
Market Cap: US$1.8b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$65.73
7D
28.2%
1Y
202.9%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.33
7D
6.2%
1Y
15.7%
Rhythm Pharmaceuticals
Market Cap: US$5.6b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$81.36
7D
-4.5%
1Y
27.5%
Aldeyra Therapeutics
Market Cap: US$90.3m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.52
7D
-5.0%
1Y
-43.9%
Pelthos Therapeutics
Market Cap: US$84.2m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$25.00
7D
7.8%
1Y
100.0%
Capricor Therapeutics
Market Cap: US$1.9b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$33.58
7D
-0.8%
1Y
163.6%
ARS Pharmaceuticals
Market Cap: US$778.5m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.26
7D
-0.5%
1Y
-41.7%
AC Immune
Market Cap: US$290.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.03
7D
2.0%
1Y
81.4%
Arcutis Biotherapeutics
Market Cap: US$2.8b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.22
7D
1.6%
1Y
58.5%
CG Oncology
Market Cap: US$5.5b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$66.74
7D
-4.5%
1Y
140.6%
Vera Therapeutics
Market Cap: US$2.6b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$35.61
7D
-7.2%
1Y
49.9%
Belite Bio
Market Cap: US$6.1b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$159.16
7D
-3.2%
1Y
157.1%
SIGA Technologies
Market Cap: US$324.5m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.60
7D
1.5%
1Y
-15.3%
Neurocrine Biosciences
Market Cap: US$13.2b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$131.67
7D
1.1%
1Y
23.5%
Verrica Pharmaceuticals
Market Cap: US$113.0m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.37
7D
-1.8%
1Y
35.4%
BeOne Medicines
Market Cap: US$32.3b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$295.27
7D
-1.5%
1Y
15.5%
Praxis Precision Medicines
Market Cap: US$9.0b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$318.83
7D
-3.3%
1Y
737.7%
Unicycive Therapeutics
Market Cap: US$180.7m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
UNCY
US$7.66
7D
4.2%
1Y
17.8%
Arcellx
Market Cap: US$6.8b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$115.07
7D
0.02%
1Y
75.6%
Mirum Pharmaceuticals
Market Cap: US$5.7b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$97.31
7D
5.8%
1Y
124.1%
Fortress Biotech
Market Cap: US$71.5m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.30
7D
3.1%
1Y
31.4%
Gyre Therapeutics
Market Cap: US$671.2m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.68
7D
3.2%
1Y
-17.8%
Journey Medical
Market Cap: US$136.7m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$5.15
7D
0.4%
1Y
-25.1%
Benitec Biopharma
Market Cap: US$416.2m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$12.05
7D
-5.1%
1Y
-16.4%
Fennec Pharmaceuticals
Market Cap: US$215.8m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.49
7D
-2.6%
1Y
6.2%
Protagonist Therapeutics
Market Cap: US$6.3b
Operates as a discovery and development company in the United States.
PTGX
US$98.97
7D
-3.6%
1Y
120.0%
Legend Biotech
Market Cap: US$4.2b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$23.52
7D
-2.0%
1Y
-30.7%
Geron
Market Cap: US$967.8m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.54
7D
2.7%
1Y
7.7%
Inovio Pharmaceuticals
Market Cap: US$91.8m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$1.12
7D
-1.8%
1Y
-40.7%
Prothena
Market Cap: US$585.2m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$11.06
7D
3.1%
1Y
26.8%
Dyadic International
Market Cap: US$28.6m
A biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.
DYAI
US$0.78
7D
-9.4%
1Y
-34.9%